Displacement of bilirubin from albumin in plasma from jaundiced newborns. An in vitro study of purified Chinese herbal constituents and sulfisoxazole.

The aim of the present study was to clarify the in vitro potential of the purified Chinese herbal constituents LZX-A (neferine), QTJ (sinomenine), YHS (tetrahydropalmitine) and SQZG (notoginsenoside R1) to displace the highly bound bilirubin from albumin binding sites in plasma from jaundiced newborn infants. Sulfisoxazole (1.32 mM) was used as a positive control for bilirubin displacement.

[Costs for treatment of very-low-birth-weight infants].

Background: The cost of treating premature infants is increasing due to use of advanced medical technology and rising labour costs. Few Norwegian studies have been published in the field. This study has assessed treatment costs for very-low-birth-weight infants in St.

[Treatment of very-low-birth-weight infants in Norway the last 40 years].

Background: Treatment of very-low-birth-weight infants has changed significantly in the last decades.

Material And Methods: Medical records were assessed retrospectively with respect to details in diagnostic and treatment characteristics for three cohorts (born in 1970, 1980 or 1989) from Rikshospitalet, Oslo and two from St. Olavs hospital (born in 1997 and 2007), Trondheim.

Displacement of bilirubin from albumin by ibuprofen in vitro.

Ibuprofen binds to plasma albumin and could interfere with the binding of bilirubin in jaundiced newborn infants. Most clinical studies have not shown increased concentrations of unbound bilirubin (UB) in plasma from infants treated with ibuprofen for a patent ductus arteriosus. However, studies in vitro have not been equally conclusive.

[Environmental toxins in breast milk].

Background: Breast milk is very important to ensure infants a well-composed and safe diet during the first year of life. However, the quality of breast milk seems to be affected by an increasing amount of environmental toxins (particularly so-called Persistent, Bioaccumulative Toxins [PBTs]). Many concerns have been raised about the negative effects this may have on infant health.

[Patent ductus arteriosus in premature infants].

Background: Patent ductus arteriosus in premature infants has often been treated because of its association with worsening of pulmonary disease and complications such as bronchopulmonary dysplasia. This view has now been challenged.

Material And Methods: Relevant publications have been identified from review articles in international peer-reviewed journals.

[Bronhopulmonary dysplasia].

Background: Since bronchopulmonary dysplasia (BPD) was first described 40 years ago, the epidemiology of premature infants has changed considerably. With improved prenatal and obstetrical care and improved/less invasive ventilatory support, severe BPD is now rarely seen in infants born after 32 weeks gestational age, but it is still the most frequent complication to severe prematurity. Depending on the diagnostic criteria, between 40-60% of the infants weighing < 1000 g at birth have BPD.